Vistagen to present at the td cowen 5th annual novel mechanisms in neuropsychiatry & epilepsy summit

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that president and chief executive officer, shawn singh, will participate in a fireside chat at the td cowen 5th annual novel mechanisms in neuropsychiatry conference. the company will also host one-on-one meetings.
COWN Ratings Summary
COWN Quant Ranking